Literature DB >> 25219368

Expression and function of aminopeptidase N/CD13 produced by fibroblast-like synoviocytes in rheumatoid arthritis: role of CD13 in chemotaxis of cytokine-activated T cells independent of enzymatic activity.

Rachel Morgan1, Judith Endres, Nilofar Behbahani-Nejad, Kristine Phillips, Jeffrey H Ruth, Sean C Friday, Gautam Edhayan, Thomas Lanigan, Andrew Urquhart, Kevin C Chung, David A Fox.   

Abstract

OBJECTIVE: Aminopeptidase N/CD13 (EC 3.4.11.2) is a metalloproteinase expressed by fibroblast-like synoviocytes (FLS). It has been suggested that CD13 can act chemotactically for T cells in rheumatoid arthritis (RA). We undertook this study to measure CD13 in vivo and in vitro in RA samples and to determine whether CD13 could play a role in the homing of T cells to the RA joint.
METHODS: Interleukin-17-treated FLS were used to immunize mice, from which a novel anti-human CD13 monoclonal antibody (mAb), 591.1D7.34, was developed. The mAb 591.1D7.34 and a second anti-CD13 mAb, WM15, were used to develop a novel enzyme-linked immunosorbent assay (ELISA) for CD13, and CD13 enzymatic activity was measured in parallel. Chemotaxis of cytokine-activated T cells was measured by a chemotaxis-under-agarose assay.
RESULTS: We detected substantial amounts of CD13 in synovial fluid (SF), sera, FLS lysates, and culture supernatants by ELISA, with a significant increase in CD13 in RA SF when compared to osteoarthritis SF. CD13 accounted for most but not all of the CD13-like enzymatic activity in SF. Recombinant human CD13 was chemotactic for cytokine-activated T cells through a G protein-coupled receptor and contributed to the chemotactic properties of SF independently of enzymatic activity.
CONCLUSION: CD13 is released from FLS into culture supernatants and is found in SF. CD13 induces chemotaxis of cytokine-activated T cells, a T cell population similar to that found in RA synovium. These data suggest that CD13 could play an important role as a T cell chemoattractant, in a positive feedback loop that contributes to RA synovitis.
Copyright © 2015 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25219368      PMCID: PMC4280337          DOI: 10.1002/art.38878

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  38 in total

1.  Loss and shedding of surface markers from the leukemic myeloid monocytic line THP-1 induced to undergo apoptosis.

Authors:  S B Brown; R M Kluck; K A Ellem
Journal:  J Cell Biochem       Date:  1996-02       Impact factor: 4.429

2.  Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid.

Authors:  P Miossec; C A Dinarello; M Ziff
Journal:  Arthritis Rheum       Date:  1986-04

3.  Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N.

Authors:  A T Look; R A Ashmun; L H Shapiro; S C Peiper
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

4.  Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production.

Authors:  J P van Hamburg; P S Asmawidjaja; N Davelaar; A M C Mus; E M Colin; J M W Hazes; R J E M Dolhain; E Lubberts
Journal:  Arthritis Rheum       Date:  2011-01

5.  Deletion of the zinc-binding motif of CD13/aminopeptidase N molecules results in loss of epitopes that mediate binding of inhibitory antibodies.

Authors:  R A Ashmun; L H Shapiro; A T Look
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

6.  CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated.

Authors:  E J Favaloro; T Browning; D Facey
Journal:  Exp Hematol       Date:  1993-12       Impact factor: 3.084

7.  Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions.

Authors:  P Chomarat; M C Rissoan; J J Pin; J Banchereau; P Miossec
Journal:  J Immunol       Date:  1995-10-01       Impact factor: 5.422

8.  T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides.

Authors:  S L Larsen; L O Pedersen; S Buus; A Stryhn
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

9.  Inactivation of interleukin-8 by aminopeptidase N (CD13).

Authors:  N Kanayama; Y Kajiwara; J Goto; E el Maradny; K Maehara; K Andou; T Terao
Journal:  J Leukoc Biol       Date:  1995-01       Impact factor: 4.962

10.  Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation.

Authors:  I Saiki; H Fujii; J Yoneda; F Abe; M Nakajima; T Tsuruo; I Azuma
Journal:  Int J Cancer       Date:  1993-04-22       Impact factor: 7.396

View more
  18 in total

Review 1.  CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.

Authors:  Chenyang Lu; Mohammad A Amin; David A Fox
Journal:  J Immunol       Date:  2020-01-01       Impact factor: 5.422

2.  Angiogenic and Arthritogenic Properties of the Soluble Form of CD13.

Authors:  Yuxuan Du; Chenyang Lu; Rachel L Morgan; William A Stinson; Phillip L Campbell; Ellen Cealey; Wenyi Fu; Nicholas J Lepore; Jonatan L Hervoso; Huadong Cui; Andrew G Urquhart; Jeffrey N Lawton; Kevin C Chung; David A Fox; Mohammad A Amin
Journal:  J Immunol       Date:  2019-06-12       Impact factor: 5.422

Review 3.  Synovial cellular and molecular markers in rheumatoid arthritis.

Authors:  M Asif Amin; David A Fox; Jeffrey H Ruth
Journal:  Semin Immunopathol       Date:  2017-05-11       Impact factor: 9.623

4.  IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells.

Authors:  Hatem A Elshabrawy; Michael V Volin; Abdul B Essani; Zhenlong Chen; Iain B McInnes; Katrien Van Raemdonck; Karol Palasiewicz; Shiva Arami; Mark Gonzalez; Hossam M Ashour; Seung-Jae Kim; Guofei Zhou; David A Fox; Shiva Shahrara
Journal:  Angiogenesis       Date:  2018-01-11       Impact factor: 9.596

5.  CD318 is a ligand for CD6.

Authors:  Gospel Enyindah-Asonye; Yan Li; Jeffrey H Ruth; Danislav S Spassov; Katie E Hebron; Andries Zijlstra; Mark M Moasser; Benlian Wang; Nora G Singer; Huadong Cui; Ray A Ohara; Stephanie M Rasmussen; David A Fox; Feng Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-31       Impact factor: 11.205

6.  The pro-inflammatory cytokine 14-3-3ε is a ligand of CD13 in cartilage.

Authors:  Meriam Nefla; Laure Sudre; Guillaume Denat; Sabrina Priam; Gwenaëlle Andre-Leroux; Francis Berenbaum; Claire Jacques
Journal:  J Cell Sci       Date:  2015-07-24       Impact factor: 5.285

Review 7.  Coronavirus Receptors as Immune Modulators.

Authors:  Charan Kumar V Devarakonda; Emily Meredith; Mallika Ghosh; Linda H Shapiro
Journal:  J Immunol       Date:  2020-12-30       Impact factor: 5.422

8.  Thyroid hormone synthesis continues despite biallelic thyroglobulin mutation with cell death.

Authors:  Xiaohan Zhang; Aaron P Kellogg; Cintia E Citterio; Hao Zhang; Dennis Larkin; Yoshiaki Morishita; Héctor M Targovnik; Viviana A Balbi; Peter Arvan
Journal:  JCI Insight       Date:  2021-06-08

9.  IRAK4 inhibition: a promising strategy for treating RA joint inflammation and bone erosion.

Authors:  Sadiq Umar; Karol Palasiewicz; Katrien Van Raemdonck; Michael V Volin; Bianca Romay; M Asif Amin; Ryan K Zomorrodi; Shiva Arami; Mark Gonzalez; Vikram Rao; Brian Zanotti; David A Fox; Nadera Sweiss; Shiva Shahrara
Journal:  Cell Mol Immunol       Date:  2020-05-15       Impact factor: 22.096

10.  Localization, Shedding, Regulation and Function of Aminopeptidase N/CD13 on Fibroblast like Synoviocytes.

Authors:  Rachel L Morgan; Nilofar Behbahani-Nejad; Judith Endres; M Asif Amin; Nick J Lepore; Yuxuan Du; Andrew Urquhart; Kevin C Chung; David A Fox
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.